Equity Investment Corp Has $116.05 Million Position in Sanofi (NASDAQ:SNY)

Equity Investment Corp reduced its holdings in Sanofi (NASDAQ:SNY - Free Report) by 2.1% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 2,406,189 shares of the company's stock after selling 52,395 shares during the quarter. Sanofi comprises 2.7% of Equity Investment Corp's portfolio, making the stock its 11th biggest holding. Equity Investment Corp owned approximately 0.09% of Sanofi worth $116,050,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in SNY. Abel Hall LLC boosted its holdings in Sanofi by 1.8% in the 4th quarter. Abel Hall LLC now owns 10,990 shares of the company's stock valued at $530,000 after purchasing an additional 194 shares during the period. PDS Planning Inc raised its position in shares of Sanofi by 3.1% during the third quarter. PDS Planning Inc now owns 6,643 shares of the company's stock valued at $383,000 after buying an additional 200 shares during the last quarter. Financial Advocates Investment Management lifted its stake in shares of Sanofi by 3.4% in the third quarter. Financial Advocates Investment Management now owns 6,327 shares of the company's stock valued at $365,000 after buying an additional 206 shares during the period. Angeles Investment Advisors LLC grew its position in Sanofi by 1.9% during the third quarter. Angeles Investment Advisors LLC now owns 11,323 shares of the company's stock worth $653,000 after buying an additional 210 shares in the last quarter. Finally, Keudell Morrison Wealth Management increased its stake in Sanofi by 1.7% during the fourth quarter. Keudell Morrison Wealth Management now owns 12,928 shares of the company's stock valued at $624,000 after acquiring an additional 217 shares during the period. 14.04% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on SNY shares. Deutsche Bank Aktiengesellschaft raised Sanofi from a "sell" rating to a "hold" rating in a report on Thursday, January 30th. Sanford C. Bernstein upgraded shares of Sanofi to a "strong-buy" rating in a research note on Thursday, January 30th. Finally, StockNews.com cut shares of Sanofi from a "buy" rating to a "hold" rating in a research note on Thursday, December 12th. Two research analysts have rated the stock with a hold rating, one has issued a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Buy" and an average price target of $60.00.

Sanofi Price Performance

Shares of SNY stock traded up $0.33 during trading hours on Friday, reaching $54.47. 1,597,658 shares of the company were exchanged, compared to its average volume of 2,389,201. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.46 and a quick ratio of 1.14. The company has a market cap of $138.24 billion, a price-to-earnings ratio of 21.88, a P/E/G ratio of 1.01 and a beta of 0.57. The stock's fifty day moving average is $51.65 and its two-hundred day moving average is $52.60. Sanofi has a fifty-two week low of $45.22 and a fifty-two week high of $58.97.

Sanofi (NASDAQ:SNY - Get Free Report) last posted its quarterly earnings data on Thursday, January 30th. The company reported $0.70 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. Sell-side analysts forecast that Sanofi will post 4.36 earnings per share for the current fiscal year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.